News
GALT
1.325
+10.42%
0.125
Galectin Therapeutics Contribution To Improve Histology Interpretation Of Cirrhotic Liver Biopsies With Machine Learning Published In Prominent Gastroenterology Journal
Benzinga · 01/24 13:12
BRIEF-Galectin Therapeutics Ends Enrollment Of Navigate, Its Seamless, Adaptive Phase 2b/3 Study Of Belapectin
Reuters · 01/05 13:52
Galectin Therapeutics: In For A Long 2-Year Wait
Seeking Alpha · 01/03 15:29
Bears are Losing Control Over Galectin Therapeutics Inc. (GALT), Here's Why It's a 'Buy' Now
Galectin Therapeutics Inc. (GALT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings e...
Zacks · 12/13/2022 14:55
Galectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of Stockholders
NORCROSS, Ga., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that management will present a corporate update via live webcast immediately foll...
GlobeNewswire · 11/29/2022 13:00
Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit
NORCROSS, Ga., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be presenting at the 6th Obesity and NASH Drug Development Sum...
GlobeNewswire · 11/28/2022 13:00
Galectin Therapeutics GAAP EPS of -$0.14
Seekingalpha · 11/14/2022 13:52
BRIEF-Galectin Therapeutics Inc Posts Qtrly Loss Per Share of $0.14
Reuters · 11/14/2022 13:08
Galectin Therapeutics Q3 EPS $(0.14), Same YoY
Benzinga · 11/14/2022 12:58
Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2022, Hosted by the AASLD
Prevalence of esophageal and gastric varices in patients with compensated NASH cirrhosis and portal hypertensionBiochemical and imaging profiles in 271 patients with compensated NASH cirrhosis and portal hypertensionHepatic Expression of Galectin-3, a Pro-...
GlobeNewswire · 11/01/2022 12:00
Galectin Therapeutics to Present in Upcoming Conferences
NORCROSS, Ga., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be presenting at two upcoming conferences. On October 17, 2022...
GlobeNewswire · 10/14/2022 12:00
Galectin rises as FDA approves to begin human trial of combination immunotherapy in head and neck cancer
Galectin Therapeutics (NASDAQ:GALT) <a href="https://s...
Seekingalpha · 10/12/2022 13:05
Galectin Therapeutics Receives FDA Approval To Proceed With Combination Immunotherapy Trial In Head And Neck Cancer
-Reuters
Benzinga · 10/12/2022 11:54
Galectin Therapeutics Files Investigational New Drug Application for Proposed Head, Neck Cancer Treatment With US FDA
Galectin Therapeutics Files Investigational New Drug Application for Proposed Head, Neck Cancer Treatment With US FDA
MT Newswires · 10/12/2022 10:37
BRIEF-Galectin Therapeutics Reports The Positive Outcome Of The Second Data And Safety Monitoring Board Meeting For Navigate, Its Seamless, Adaptive Phase 2B/3 Study Of Belapectin In Patients With Liver Cirrhosis Caused By Non-Alcoholic Steatohepatitis
BRIEF-Galectin Therapeutics Reports The Positive Outcome Of The Second Data And Safety Monitoring Board Meeting For Navigate, Its Seamless, Adaptive Phase 2B/3 Study Of Belapectin In Patients With Liver Cirrhosis Caused By Non-Alcoholic Steatohepatitis
Reuters · 10/06/2022 12:17
Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022
NORCROSS, Ga., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 24th Annual Global In...
GlobeNewswire · 09/08/2022 12:00
Galectin Therapeutics GAAP EPS of -$0.16
Galectin Therapeutics press release (<span cla...
Seekingalpha · 08/15/2022 12:42
BRIEF-Galectin Therapeutics Quarterly Loss Per Share $0.16
BRIEF-Galectin Therapeutics Quarterly Loss Per Share $0.16
Reuters · 08/15/2022 12:07
BRIEF-Galectin Therapeutics Announces $60 Million Credit Line From Richard E. Uihlein Sufficient To Cover Expected Expenditures Through 2024
BRIEF-Galectin Therapeutics Announces $60 Million Credit Line From Richard E. Uihlein Sufficient To Cover Expected Expenditures Through 2024
Reuters · 07/26/2022 12:17
Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024
NORCROSS, Ga., July 26, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today it entered into a $60 million unsecured line of credit facility with its chairma...
GlobeNewswire · 07/26/2022 12:00
More
Webull provides a variety of real-time GALT stock news. You can receive the latest news about Galectin Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About GALT
Galectin Therapeutics Inc. is a biotechnology company that is focused on developing therapies to improve the lives of patients with fibrotic disease, chronic liver disease and cancer. The Company’s product candidates include galectin-3 inhibitor, which is a belapectin (GR-MD-02) and GM-CT-01. The Company’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The Company is using a galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis (NASH) patients. The Company also designed a Phase IIb/III clinical study, the NAVIGATE trial, evaluating the safety and efficacy of its galectin-3 inhibitor, belapectin (GR-MD-02), for the prevention of esophageal varices in patients with non-alcoholic steatohepatitis cirrhosis.